Follow Arrowhead Pharmaceuticals to never miss an important update.
Stifel Nicolaus raised its price target from $98 to $104. This adjustment comes after the company reported higher-than-expected revenue and shared positive data for its drug plozasiran, which aims to treat severe triglyceride disorders. While the stock currently trades around $86, this higher target suggests analysts see room for the price to rise as the company moves closer to launching new treatments.
Source: Stifel Nicolaus
Arrowhead brought in $80 million in revenue for the quarter, doubling the $40 million that analysts expected. This growth was driven by REDEMPLO, the company's first drug sold by its own sales team rather than a larger partner. While the company lost $1.36 per share, slightly more than the $1.28 loss expected, this is normal for a biotech firm spending heavily to launch new medicines and run clinical trials.
The company also confirmed that its next major drug, plozasiran, met its goals in two late-stage studies for severe hypertriglyceridemia, a condition that causes dangerously high fat levels in the blood. Management plans to file for expanded approval by the end of 2026. This progress is a key step in proving the company can transition from a research lab into a profitable pharmaceutical business.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Arrowhead has purchased a Priority Review Voucher from an undisclosed seller. These vouchers are granted by the FDA to encourage research into rare diseases and can be used to shorten the agency's review time for a new drug from the standard ten months to just six.
The company plans to use this voucher for plozasiran, its treatment for severe hypertriglyceridemia, when it submits the drug for approval later this year. By spending cash to buy this voucher, Arrowhead is betting that getting the drug to market four months early will more than pay for itself through earlier sales and a faster start against competitors.
Source: Business Wire
The company has finished enrolling patients in its YOSEMITE trial. This study tests zodasiran in people with a rare genetic condition that causes extremely high cholesterol levels from a young age, often leading to early heart disease.
Completing enrollment is a key milestone because it sets a clear timeline for when the company will get the final results. If the data is positive, it would allow Arrowhead to seek approval for another drug in its cardiovascular pipeline, further diversifying its business beyond its first few products.
Source: Business Wire
H.C. Wainwright raised its price target for Arrowhead from $100 to $115. The move reflects growing confidence in the company's heart-related drug pipeline after successful results in late-stage trials. This higher target suggests the firm believes the company's technology is becoming more valuable as it moves closer to getting more drugs approved for sale.
Source: H.C. Wainwright
The company has a history of choppy results because its income often depends on large, one-time payments from partners. This makes the headline profit numbers less reliable than the actual drug sales.
| Expectation | |
|---|---|
| EPS | $-1.52 |
| Revenue | $72M |
Follow Arrowhead Pharmaceuticals to get the latest and most important updates.
Follow ARWR